The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-escalation, pharmacokinetic (PK), and pharmacodynamic (PD) evaluation of intravenous LY2090314 a GSK3 inhibitor administered in combination with pemetrexed and carboplatin.
L. H. Brail
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
J. E. Gray
Consultant or Advisory Role - Lilly
Honoraria - Lilly
H. Burris
No relevant relationships to disclose
G. R. Simon
Consultant or Advisory Role - Lilly
Honoraria - Lilly
J. Cooksey
No relevant relationships to disclose
S. F. Jones
No relevant relationships to disclose
D. Farrington
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
T. Lam
Consultant or Advisory Role - Lilly
K. Jackson
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
K. Chow
Employment or Leadership Position - Lilly
J. T. Brandt
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
J. R. Infante
No relevant relationships to disclose